Supernus Pharmaceuticals (SUPN) Insider Trading & Ownership $35.17 -0.26 (-0.73%) (As of 10:31 AM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Supernus Pharmaceuticals (NASDAQ:SUPN) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage9.30%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$7.11 M Get SUPN Insider Trade Alerts Want to know when executives and insiders are buying or selling Supernus Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address SUPN Insider Buying and Selling by Quarter Ad ProsperityPubIf you see ONE chart today… make it this one$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING.And expects this underappreciated niche to continue rallying well into 2026. Supernus Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/7/2024Frank MottolaSVPSell15,000$36.98$554,700.00 11/7/2024Georges GemayelDirectorSell14,213$36.62$520,480.06 11/7/2024Jack A KhattarCEOSell125,000$36.68$4,585,000.00 3/21/2024Padmanabh P BhattVPSell14,491$35.31$511,677.21 3/19/2024Padmanabh P BhattVPSell12,364$35.31$436,572.84 3/12/2024Padmanabh P BhattVPSell3,884$32.99$128,133.16 2/26/2024Padmanabh P BhattVPSell5,000$30.21$151,050.00 1/10/2024Tami Tillotson MartinVPSell8,000$27.91$223,280.00 (Data available from 1/1/2013 forward) SUPN Insider Trading Activity - Frequently Asked Questions Who is on Supernus Pharmaceuticals's Insider Roster? The list of insiders at Supernus Pharmaceuticals includes Frank Mottola, Frederick M Hudson, Georges Gemayel, Jack A Khattar, Padmanabh P Bhatt, and Tami Tillotson Martin. Learn more on insiders at SUPN. What percentage of Supernus Pharmaceuticals stock is owned by insiders? 9.30% of Supernus Pharmaceuticals stock is owned by insiders. Learn more on SUPN's insider holdings. Which Supernus Pharmaceuticals insiders have been selling company stock? The following insiders have sold SUPN shares in the last 24 months: Frank Mottola ($757,956.50), Frederick M Hudson ($259,150.50), Georges Gemayel ($520,480.06), Jack A Khattar ($6,213,625.74), Padmanabh P Bhatt ($1,427,029.73), and Tami Tillotson Martin ($644,694.65). How much insider selling is happening at Supernus Pharmaceuticals? Insiders have sold a total of 271,124 Supernus Pharmaceuticals shares in the last 24 months for a total of $9,822,937.18 sold. Supernus Pharmaceuticals Key ExecutivesMr. Jack A. Khattar (Age 63)Founder, President, CEO, Secretary & Director Compensation: $1.63M1 recent tradesMr. Timothy C. Dec (Age 65)Senior VP & CFO Compensation: $635.43kDr. Padmanabh P. Bhatt Ph.D. (Age 67)Chief Scientific Officer & Senior VP of Intellectual Property Compensation: $594.14kMr. Frank Mottola (Age 52)Senior Vice President of Quality, GMP Operations & Information Technology Compensation: $490.87k1 recent tradesDr. Jonathan Rubin M.D. (Age 63)MBA, Senior VP of Research & Development and Chief Medical Officer Compensation: $594.65kMr. Kevin T. Anderson (Age 62)Compliance Officer Dr. Todd Horich M.B.A.Ph.D., Senior Vice President of Marketing & Market AccessMr. Taylor RaifordSenior Vice President of SalesDr. Bryan A. Roecklein Ph.D.Senior Vice President of Corporate DevelopmentMs. Tami T. Martin Esq. (Age 69)R.N., Senior Vice President of Regulatory Affairs Compensation: $508.5k More Insider Trading Tools from MarketBeat Related Companies JAZZ Insider Selling CORT Insider Selling PRGO Insider Selling PCRX Insider Selling OMER Insider Selling NKTR Insider Selling ASMB Insider Selling CPIX Insider Selling LLY Insider Selling JNJ Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:SUPN) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredCackling Kamala hates this companyDo you want to see one of the most exciting election trades of all time? A trade that could help America b...DTI | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMysterious drone activity triggers massive 1,366% surgeIf mysterious drones buzzing over the East Coast weren’t on your radar this year, you’re not alone. But her...Insiders Exposed | SponsoredIf you see ONE chart today… make it this one$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Go...ProsperityPub | Sponsored70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all po...WealthPress | SponsoredHow Low-Cost Stocks Generate Monthly IncomeAre you ready to transform your investment strategy and generate a steady monthly income? We’re excited to ...Darwin | SponsoredVacuum up cash with these special trades? Have you ever heard about a “volatility vacuum?” Most people haven’t. It all revolves around this formu...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SUPN Stock Alerts